Rita Leporati
Overview
Explore the profile of Rita Leporati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Urtecho S, Provenzano L, Spagnoletti A, Bottiglieri A, Pircher C, Massa G, et al.
Lung Cancer
. 2024 Dec;
199:108051.
PMID: 39740426
Introduction: KRAS mutation the most common molecular alteration in advanced non-small cell lung cancer (NSCLC) and is associated with an unfavourable prognosis, largely due to the lack of targeted therapeutic...
2.
Leporati R, Auclin E, Morchon D, Ferriol-Galmes M, Laguna J, Gorria T, et al.
Ther Adv Med Oncol
. 2024 Dec;
16:17588359241306940.
PMID: 39697619
Background: While targeted therapies have transformed the treatment landscape of oncogene-addicted non-small cell lung cancer (NSCLC), the influence of sex on treatment outcomes remains insufficiently understood. Objectives: This systematic review...
3.
Ambrosini P, Miliziano D, Liberti G, Lorenzini D, Marchesi S, Bassetti A, et al.
Clin Lung Cancer
. 2024 Dec;
26(1):e11-e17.
PMID: 39665942
No abstract available.
4.
Gomez-Randulfe I, Silva Diaz S, Escriu C, Mohammed S, Shah R, Benitez Fuentes J, et al.
Ther Adv Med Oncol
. 2024 Oct;
16:17588359241272957.
PMID: 39355343
Background And Objectives: Second-line treatment for small-cell lung cancer (SCLC) is primarily guided by the time elapsed since the last platinum dose. Rechallenge with carboplatin and etoposide has demonstrated superior...
5.
Occhipinti M, Brambilla M, Di Liello R, Ambrosini P, Lobianco L, Leporati R, et al.
Crit Rev Oncol Hematol
. 2024 Sep;
204:104521.
PMID: 39317528
No abstract available.
6.
Occhipinti M, Brambilla M, Di Liello R, Ambrosini P, Lobianco L, Leporati R, et al.
Crit Rev Oncol Hematol
. 2024 Aug;
203:104481.
PMID: 39159705
This review delves into the intricate landscape of pleural mesothelioma (PM), emphasizing the need for nuanced therapeutic strategies. While platinum-based chemotherapy remains a cornerstone, the advent of immune checkpoint inhibitors...
7.
Angerilli V, Sabella G, Simbolo M, Lagano V, Centonze G, Gentili M, et al.
Br J Cancer
. 2024 May;
131(1):159-170.
PMID: 38729995
Background: High-grade gastro-entero-pancreatic neoplasms (HG GEP-NENs) can be stratified according to their morphology and Ki-67 values into three prognostic classes: neuroendocrine tumors grade 3 (NETs G3), neuroendocrine carcinomas with Ki-67 ...
8.
Leporati R, Miliziano D, Beninato T, Mazzeo L, Manglaviti S, Brambilla M, et al.
Tumori
. 2024 Apr;
110(6):NP1-NP4.
PMID: 38623748
Introduction: Several anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have been developed for the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-ALK-rearranged non-small cell lung cancer (NSCLC), with the newer...
9.
Gomez-Randulfe I, Leporati R, Gupta B, Liu S, Califano R
Eur J Cancer
. 2024 Feb;
200:113581.
PMID: 38301317
Recent advancements in treating extensive-stage small-cell lung cancer (ES-SCLC) have been significantly marked by incorporating immune checkpoint inhibitors (ICIs) into platinum-based chemotherapy, leading to modest yet notable improvements in patient...
10.
Prelaj A, Ganzinelli M, Provenzano L, Mazzeo L, Viscardi G, Metro G, et al.
Clin Lung Cancer
. 2024 Jan;
25(2):190-195.
PMID: 38262770
Introduction: Despite several therapeutic efforts, lung cancer remains a highly lethal disease. Novel therapeutic approaches encompass immune-checkpoint inhibitors, targeted therapeutics and antibody-drug conjugates, with different results. Several studies have been...